Pasithea Therapeutics Ownership
| KTTA Stock | USD 0.69 0.01 1.43% |
Pasithea Stock Ownership Analysis
About 13.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.39. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pasithea Therapeutics recorded a loss per share of 10.6. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 2nd of January 2024. Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida. Pasithea Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Pasithea Therapeutics Corp contact Tiago Marques at 786 977 3380 or learn more at https://www.pasithea.com.Besides selling stocks to institutional investors, Pasithea Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pasithea Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pasithea Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pasithea Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Pasithea Therapeutics Corp are currently held by insiders. Unlike Pasithea Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pasithea Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pasithea Therapeutics' insider trades
Pasithea Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pasithea Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pasithea Therapeutics Corp backward and forwards among themselves. Pasithea Therapeutics' institutional investor refers to the entity that pools money to purchase Pasithea Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisorshares Investments, Llc | 2025-03-31 | 53.5 K | Citigroup Inc | 2025-03-31 | 13.7 K | Ubs Group Ag | 2025-03-31 | 4.3 K | Hurley Capital, Llc | 2025-03-31 | 3.7 K | Tower Research Capital Llc | 2025-03-31 | 3.3 K | Jpmorgan Chase & Co | 2025-03-31 | 150 | Bank Of America Corp | 2025-03-31 | 8.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Royal Bank Of Canada | 2025-03-31 | 0.0 | Armistice Capital, Llc | 2025-03-31 | 0.0 |
Pasithea Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pasithea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pasithea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pasithea Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pasithea Therapeutics Outstanding Bonds
Pasithea Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pasithea Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pasithea bonds can be classified according to their maturity, which is the date when Pasithea Therapeutics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.60) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.